NEW YORK, Feb. 26, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on RARE, QURE, VRTX, and VVUS which can be accessed for free by signing up to www.wallstequities.com/registration. WallStEquities.com shifts focus on the global Biotechnology market, which is mainly driven by the surge in the demand for food, depleting natural resources, government regulatory support, and technological advancements of various solutions to counter fatal diseases. Stocks in today's lineup are: Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), uniQure N.V. (NASDAQ: QURE), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), and VIVUS Inc. (NASDAQ: VVUS). All you have to do is sign up today for this free limited time offer by clicking the link below.
www.wallstequities.com/registration
Ultragenyx Pharmaceutical
Novato, California headquartered Ultragenyx Pharmaceutical Inc.'s shares recorded a trading volume of 533,173 shares last Friday. The stock finished the trading session 0.44% higher at $47.86. The Company's shares are trading below their 50-day moving average by 1.78%. Furthermore, shares of Ultragenyx Pharma, which focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the US, have a Relative Strength Index (RSI) of 48.14.
On January 29th, 2018, Ultragenyx Pharmaceutical announced that it has appointed Camille L. Bedrosian, M.D. as Executive Vice President and
Chief Medical Officer. In this role, Dr. Bedrosian will provide strategic leadership to the clinical development and translational research programs, and will oversee Medical Affairs, Global Clinical Development groups, Clinical Operations, and Drug Safety/Pharmacovigilance.
On February 21st, 2018, research firm Stifel reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $85 a share to $74 a share. Get the full research report on RARE for free by clicking below at:
www.wallstequities.com/registration/?symbol=RARE
uniQure
On Friday, Amsterdam, the Netherlands headquartered uniQure N.V.'s stock ended the session 1.39% lower at $25.53. A total volume of 310,223 shares was traded. The Company's shares have surged 30.06% in the last month, 71.00% over the previous three months, and 336.41% over the past year. The stock is trading 30.59% above its 50-day moving average and 113.36% above its 200-day moving average. Moreover, shares of uniQure, which engages in the discovery, development, and commercialization of gene therapies in the Netherlands, have an RSI of 74.32.
On February 01st, 2018, uniQure announced that members of Company management or principal investigators will participate in the 13th Annual Huntington's Disease Therapeutics Conference, which takes place from February 26th, 2018, to March 01st, 2018 at the Parker Hotel in Palm Springs, California. Investigators at the Centre for Molecular Medicine and Therapeutics & BC Children's Hospital Research Institute, University of British Columbia, Vancouver, Canada, will present novel, preclinical data on the Company's proprietary investigational gene therapy, AMT-130, in humanized mice models of Huntington's disease. The free technical report on QURE can be accessed at:
www.wallstequities.com/registration/?symbol=QURE
Vertex Pharmaceuticals
Boston, Massachusetts headquartered Vertex Pharmaceuticals Inc.'s stock ended the day 5.27% higher at $165.90 with a total trading volume of 1.57 million shares. The Company's shares have gained 14.33% over the previous three months and 93.51% over the past year. The stock is trading 6.50% and 13.48% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Vertex Pharma, which discovers, develops, manufactures, and commercializes medicines for serious diseases, have an RSI of 59.91.
On February 13th, 2018, research firm JMP Securities reiterated its 'Market Outperform' rating on the Company's stock with an increase of the target price from $200 a share to $211 a share.
On February 21st, 2018, Vertex Pharmaceuticals announced that it is initiating the first Phase-3 study of VX-659, tezacaftor and ivacaftor as an investigational triple combination regimen for people with cystic fibrosis, who have one F508del mutation and one minimal function mutation. The study will enroll 360 patients, and the primary endpoint of the study is the mean absolute change from baseline in percent predicted forced expiratory volume in one second at week four of treatment. Sign up for free on Wall St. Equities and claim the latest report on VRTX at:
www.wallstequities.com/registration/?symbol=VRTX
VIVUS
Shares in Campbell, California headquartered VIVUS Inc. recorded a trading volume of 266,129 shares. The stock ended Friday's session 1.81% lower at $0.47. The Company's shares have gained 0.28% in the last month. The stock is trading below its 50-day moving average by 4.12%. Furthermore, shares of VIVUS, which develops and commercializes therapies to address unmet medical needs in the US and the European Union, have an RSI of 51.38. See the free research coverage on VVUS at:
www.wallstequities.com/registration/?symbol=VVUS
--
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
https://wallstequities.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@wallstequities.com
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/quotidian-technical-highlights-on-selected-biotech-stocks----ultragenyx-pharma-uniqure-vertex-pharma-and-vivus-300603912.html
SOURCE Wall St. Equities
